Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
ANN ARBOR, Mich., Feb. 20, 2018 -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today announced its participation in the Bank of America Merrill Lynch Animal Health Summit on Monday, February 26, 2018, in New York, NY.
Chief Financial Officer Shameze Rampertab, CPA, CA, is part of a panel discussion on “Innovation in Companion Animal Therapeutics” at 8:40 a.m. E.T. and will be available to participate in one-on-one meetings to discuss Zomedica’s pipeline development and key milestones with investors registered to attend the conference.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) (TSX-V:ZOM) is a veterinary diagnostic and pharmaceutical company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. With a team that includes clinical veterinary professionals, it is Zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Follow Zomedica
- Email Alerts: http://investors.zomedica.com/
- LinkedIn: https://www.linkedin.com/company/zomedica
- Facebook: https://www.facebook.com/zomedica/
- Twitter: https://twitter.com/zomedica
Reader Advisory
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.
Investor Relations Contact
Shameze Rampertab, CPA, CA
[email protected]
+1 647.283.3630
PCG Advisory Group
Kirin Smith, COO
[email protected]
+1 646.863.6519
www.pcgadvisory.com
Media Contact
Andrea Eberle
[email protected]
+1 734.369.2555
